Table 1.

Demographic and Clinical Characteristics of Included Subjects in Antibiotic-Associated Diarrhea and Asymptomatic Control Groups

	Study Cohort (N = 300)	AAD Group (n = 200)	Asymptomatic Control Group (n = 100)	P
Age, years
ȃ Median (IQR)	20 (9–59)	20 (11–59)	19 (6–59)	.1
ȃ Range	2–94	2–94	2–85
Sex (male)	155 (51.7%)	105 (52.5%)	50 (50%)	.68
Race/ethnicity				.22
ȃ Asian	11 (3.7%)	6 (3%)	5 (5%)
ȃ American Indian/Alaska Native	0 (0%)	0 (0%)	0 (0%)
ȃ Black	64 (21.3%)	36 (18%)	28 (28%)
ȃ Native Hawaiian/other Pacific Islander	0 (0%)	0 (0%)	0 (0%)
ȃ White	169 (56.3%)	119 (59.5%)	50 (50%)
Unknown	6 (2%)	1 (1%)	5 (2.5%)
ȃ Other	50 (16.7%)	16 (16%)	34 (17%)
Ethnicity				.09
ȃ Hispanic or Latino	57 (19%)	42 (21%)	15 (15%)
ȃ Not Hispanic or Latino	237 (79%)	85 (85%)	152 (76%)
ȃ Unknown	6 (2%)	0 (0%)	6 (3%)
Comorbidities
ȃ Any comorbid condition	273 (91%)	186 (93%)	87 (87%)	.09
ȃ Malignancy/stem cell transplant	95 (31 7%)	74 (37%)	21 (21%)	.005*
ȃ IBD	6 (2%)	6 (3%)	0 (0%)	.08
ȃ Non-IBD gastrointestinal condition	34 (11.3%)	30 (15%)	4 (4%)	.005*
ȃ Solid-organ transplant	32 (10.7%)	25 (12.5%)	7 (7%)	.15
ȃ Other immunocompromising condition	21 (7%)	18 (9%)	3 (3%)	.06
ȃ Cardiovascular	99 (33%)	60 (30%)	39 (39%)	.12
ȃ Liver	7 (2.3%)	5 (2.5%)	2 (2%)	.79
ȃ Kidney	32 (10.7%)	22 (11%)	10 (10%)	.79
ȃ Pulmonary	20 (6 7%)	6 (3%)	14 (14%)	<.001*
ȃ Endocrine/diabetes	34 (11 3%)	21 (10.5%)	13 (13%)	.52
Antibiotic exposure (past 30 days)
ȃ Any systemic antibiotic	263 (87.7%)	200 (100%)	63 (63%)	<.001*
ȃ Third-/fourth-generation cephalosporin	103 (34.3%)	78 (39%)	25 (25%)	.02*
ȃ Clindamycin	16 (5.3%)	8 (4%)	8 (8%)	.15
ȃ Fluoroquinolone	45 (15%)	39 (19.5%)	6 (6%)	.002*

Data are presented as n (%) unless otherwise indicated. *P < .05 (P value compares AAD group and asymptomatic control group).

Abbreviations: AAD, antibiotic-associated diarrhea; IBD, inflammatory bowel disease; IQR, interquartile range.